The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study
Creators: name: Quattrone, Diego
name: Reininghaus, Ulrich
name: Richards, Alex L.
name: Tripoli, Giada
name: Ferraro, Laura
name: Quattrone, Andrea
name: Marino, Paolo
name: Rodriguez, Victoria
name: Spinazzola, Edoardo
name: Gayer-Anderson, Charlotte
name: Jongsma, Hannah E.
name: Jones, Peter B.
name: La Cascia, Caterina
name: La Barbera, Daniele
name: Tarricone, Ilaria
name: Bonora, Elena
name: Tosato, Sarah
name: Lasalvia, Antonio
name: Szöke, Andrei
name: Arango, Celso
name: Bernardo, Miquel
name: Bobes, Julio
name: Del Ben, Cristina Marta
name: Menezes, Paulo Rossi
name: Llorca, Pierre-Michel
name: Santos, Jose Luis
name: Sanjuán, Julio
name: Arrojo, Manuel
name: Tortelli, Andrea
name: Velthorst, Eva
name: Berendsen, Steven
name: De Haan, Lieuwe
name: Rutten, Bart P. F.
name: Lynskey, Michael T.
name: Freeman, Tom P.
name: Kirkbride, James B.
name: Sham, Pak C.
name: O’Donovan, Michael C.
name: Cardno, Alastair G.
name: Vassos, Evangelos
name: Van Os, Jim
name: Morgan, Craig
name: Murray, Robin M.
name: Lewis, Cathryn M.
name: Di Forti, Marta
name: Hubbard, Kathryn
name: Beards, Stephanie
name: Stilo, Simona A.
name: Parellada, Mara
name: Fraguas, David
name: Castro, Marta Rapado
name: Andreu-Bernabeu, Álvaro
name: López, Gonzalo
name: Matteis, Mario
name: González, Emiliano
name: Durán-Cutilla, Manuel
name: Díaz-Caneja, Covadonga M.
name: Cuadrado, Pedro
name: Rodríguez Solano, José Juan
name: Carracedo, Angel
name: Costas, Javier
name: Sánchez, Emilio
name: Amoretti, Silvia
name: Lorente-Rovira, Esther
name: Garcia-Portilla, Paz
name: Jiménez-López, Estela
name: Franke, Nathalie
name: Van Dam, Daniella
name: Termorshuizen, Fabian
name: Van Der Ven, Elsje
name: Messchaart, Elles
name: Leboyer, Marion
name: Schürhoff, Franck
name: Jamain, Stéphane
name: Baudin, Grégoire
name: Ferchiou, Aziz
name: Pignon, Baptiste
name: Richard, Jean-Romain
name: Charpeaud, Thomas
name: Tronche, Anne-Marie
name: Frijda, Flora
name: Marrazzo, Giovanna
name: Sideli, Lucia
name: Sartorio, Crocettarachele
name: Seminerio, Fabio
name: Loureiro, Camila Marcelino
name: Shuhama, Rosana
name: Ruggeri, Mirella
name: Bonetto, Chiara
name: Cristofalo, Doriana
name: Berardi, Domenico
name: Seri, Marco
name: D’Andrea, Giuseppe
Publisher: name: Apollo - University of Cambridge Repository
Year: 2021
Subjects: Article
/692/699/476/1799
/631/208/2489
/692/53/2423
/45
/45/43
article

description: Abstract: Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms and experiences using item response bi-factor modelling. Linear regression was used to test the associations between these dimensions and SZ-PRS, as well as the combined effect of SZ-PRS and cannabis use on the dimensions of positive psychotic symptoms and experiences. We found associations between SZ-PRS and (1) both negative (B = 0.18; 95%CI 0.03–0.33) and positive (B = 0.19; 95%CI 0.03–0.35) symptom dimensions in 617 FEP patients, regardless of their categorical diagnosis; and (2) all the psychotic experience dimensions in 979 controls. We did not observe associations between SZ-PRS and the general and affective dimensions in FEP. Daily and current cannabis use were associated with the positive dimensions in FEP (B = 0.31; 95%CI 0.11–0.52) and in controls (B = 0.26; 95%CI 0.06–0.46), over and above SZ-PRS. We provide evidence that genetic liability to schizophrenia and cannabis use map onto transdiagnostic symptom dimensions, supporting the validity and utility of the dimensional representation of psychosis. In our sample, genetic liability to schizophrenia correlated with more severe psychosis presentation, and cannabis use conferred risk to positive symptomatology beyond the genetic risk. Our findings support the hypothesis that psychotic experiences in the general population have similar genetic substrates as clinical disorders.